Breaking News Instant updates and real-time market news.

SNY

Sanofi

$37.73

-0.22 (-0.58%)

, GSK

GlaxoSmithKline

$42.39

0.31 (0.74%)

18:12
10/13/16
10/13
18:12
10/13/16
18:12

Florida Health Dept: Five new travel related Zika cases, two new non-travel case

The Florida Department of Health said that there are five new travel related Zika cases today with one in Hillsborough, one in Orange, one in Pinellas and two involving pregnant women. There are two new non-travel related cases, the deparment added. One case is linked to the new area of local transmission in Miami-Dade County. The other case is a Broward County resident and the department is investigating to determine where exposure occurred. DOH has confirmed through its ongoing investigation that local transmission of Zika is occurring in a new small area in Miami-Dade County. The street boundaries are NW 79th St. to the North, NW 63rd St. to the South, NW 10th Ave. to the West and N. Miami Ave. to the East. The department has identified five people, two women and three men, in the new area. Three live in this one square mile area. The other two either work or have visited this area. Four of these cases have already been announced and were under the normal investigation process. The investigation of the final case was completed today. Publicly traded companies in the Zika space include Sanofi (SNY), GlaxoSmithKline (GSK), Intrexon (XON), Inovio (INO), Cerus (CERS), Chembio Diagnostics (CEMI), and NewLink Genetics (NLNK). Reference Link

SNY

Sanofi

$37.73

-0.22 (-0.58%)

GSK

GlaxoSmithKline

$42.39

0.31 (0.74%)

XON

Intrexon

$27.29

-0.27 (-0.98%)

INO

Inovio

$8.75

-0.09 (-1.02%)

CERS

Cerus

$5.18

-0.34 (-6.16%)

CEMI

Chembio Diagnostics

NLNK

NewLink Genetics

$14.95

-0.65 (-4.17%)

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 15

    Nov

  • 29

    Nov

  • 29

    Mar

SNY Sanofi
$37.73

-0.22 (-0.58%)

10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Neutral
Sanofi upgraded to Neutral from Underperform at Exane BNP Paribas
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Sanofi initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Sanofi with a Neutral rating and EUR 76 price target.
GSK GlaxoSmithKline
$42.39

0.31 (0.74%)

10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/03/16
RBCM
10/03/16
NO CHANGE
Target $95
RBCM
Outperform
Gilead HIV franchise could see risk from competitor data, says RBC Capital
RBC Capital analyst Michael Yee said his conversations with doctors leads him to think two dolutegravir HIV "doublet" studies being conducted by GlaxoSmithKline (GSK) and ViiV Healthcare - Glaxo's joint venture with Pfizer (PFE) and Shionogi - are likely to work and present an underappreciated risk to Gilead's (GILD) HIV franchise. Talks with investors lead Yee to believe few are even aware of this risk and that the consensus view is underestimating the probability these non-inferiority trials will work. Arguing that the consensus view should factor in more conservative assumptions for Gilead's HIV business post 2018 due to this risk, Yee cut his price target on Gilead to $95 from $105, but keeps an Outperform rating on the shares.
09/23/16
09/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Morgan Stanley analyst Brian Nowak initiated Activision Blizzard (ATVI) and Electronic Arts (EA), both with Overweight ratings. The analyst is bullish on the digital gaming shift away from "units sold" to a business model based on users, engagement, and digital monetization. He sees digital in-game offerings resulting in recurring and growth user bases, increased per-game engagement, and further monetization opportunities. 2. AstraZeneca (AZN) and GlaxoSmithKline (GSK) both initiated with Overweight ratings by Piper Jaffray analyst Richard Purkiss. 3. Achillion (ACHN) initiated with an Outperform by Wedbush analyst Heather Behanna, who set a $13 price target on the shares. 4. Sysco (SYY) initiated with an Underweight at Barclays and $48 price target by analyst Karen Short. 5. Five Below (FIVE), Dollar Tree (DLTR) and Dollar General (DG) all initiated with Equal Weight ratings by Barclays analyst Karen Short. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/23/16
PIPR
09/23/16
INITIATION
PIPR
Overweight
GlaxoSmithKline initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started GlaxoSmithKline with an Overweight rating and GBP 20 price target. The company's growth is defensive and its risks are declining, Purkiss tells investors in a research note.
XON Intrexon
$27.29

-0.27 (-0.98%)

05/03/16
05/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wal-Mart (WMT) initiated with an Underperform at RBC Capital due to a negative risk/reward ratio, citing the company's massive size, intensifying competition and the shift towards e-commerce. 2. Costco (COST) initiated with an Outperform at RBC Capital with the firm saying that the company's membership fees provide it with "a growing, high margin revenue stream," while it has " some of the best/most consistent customer traffic growth in all of retail." 3. Kroger (KR) initiated with a Neutral at SunTrust. 4. H&R Block (HRB) initiated with a Neutral at Sterne Agee CRT. 5. Intrexon (XON) initiated with an Outperform at JMP Securities by analyst Jason Butler, who said Intrexon has a "highly scalable" business model and has achieved technological and regulatory validation in the areas of food, health, and the environment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/16
STFL
05/11/16
NO CHANGE
Target $57
STFL
Buy
Intrexon appears to be making incremental progress, says Stifel
Stifel analyst Thomas Shrader acknowledges that Intrexon's Q1 results press release and associated call were "highly complex" and the stock remains "highly polarizing," but he believes the company is making incremental progress, that the potential deployment of its mosquitoes to combat Zika seems to be advancing, and noted that its gas to liquid bioconversion programs were reported to be in the "red zone" of development. The company appears to be increasingly focused on non-therapeutic and non-medical projects and Shrader continues to view its gas to liquid energy conversion program as the highest value opportunity at Intrexon, he told investors in a post-earnings research note. The firm keeps a Buy rating and $57 price target on Intrexon shares.
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
09/08/16
JMPS
09/08/16
NO CHANGE
JMPS
Intrexon could benefit from Zika eradication efforts, says JMP Securities
JMP Securities analyst Jason Butler notes that a bipartisan group of Florida House members and the leaders of the state's Pinellas County asked the federal government to grant a waiver that would allow the use of Intrexon's Friendly Aedes for Zika eradication efforts. The analyst says that a waiver could result in "nearer term government orders." He keeps a $42 price target and Outperform rating on Intrexon.
INO Inovio
$8.75

-0.09 (-1.02%)

10/04/16
BMUR
10/04/16
INITIATION
Target $18
BMUR
Buy
Inovio assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Inovio Pharmaceuticals with a Buy rating and $18 price target.
08/09/16
MAXM
08/09/16
DOWNGRADE
MAXM
Hold
Inovio downgraded to Hold from Buy at Maxim
01/22/16
MAXM
01/22/16
NO CHANGE
MAXM
Inovio mentioned positively at Maxim
02/19/16
PIPR
02/19/16
NO CHANGE
Target $31
PIPR
Overweight
Piper highlights Inovio amid spread of Zika
Piper Jaffray analyst Charles Duncan highlights Inovio Pharmaceuticals as the Zika virus spreads, calling the company a leader among potential vaccine players. The company's SynCon technology has a "higher than usual probability of clinical success" in Zika given its experience with other flaviviruses and tropical diseases, Duncan tells investors in a research note. He has an Overweight rating on Inovio with a $31 price target. The stock closed yesterday down 47c to $6.45.
CERS Cerus
$5.18

-0.34 (-6.16%)

08/03/16
CANT
08/03/16
NO CHANGE
Target $9
CANT
Buy
Cantor sees Zika headlines as catalyst for Cerus shares
Cantor Fitzgerald analyst Bryan Brokmeier recommends buying shares of Cerus ahead of tomorrow's Q2 earnings report. The analyst believes the growing awareness and fear of Zika, especially during the Olympics, which start on August 5, may drive shares of companies that are involved in combating Zika higher. He reminds investors that Cerus offers the only FDA approved pathogen inactivation technology and was recently included in the agency's guidance document for reducing the risk of transfusion-transmission of Zika. The greatest opportunity for Cerus is on the Gulf Coast, which provides $29.7M and $26.2M of revenue opportunities for platelet and plasma, respectively, Brokmeier tells investors in an intraday research note. He keeps a Buy rating on the shares with a $9 price target.
08/05/16
CANT
08/05/16
NO CHANGE
CANT
Cerus should be bought after results, says Cantor
Cantor analyst Bryan Brokmeier recommends buying Cerus stock after the company reported Q2 results that he calls "solid." The analyst says that the company's regulatory program for red cells is on track. He keeps a $9 price target and Buy rating on the shares.
08/26/16
CANT
08/26/16
NO CHANGE
Target $9
CANT
Buy
Cantor says buy Cerus following FDA industry guidance
Cantor analyst Bryan Brokmeier says investors should buy shares of Cerus following the FDA's revised industry guidance recommending all blood centers across the U.S. implement either blood testing for the Zika Virus or FDA approved pathogen-reduction technology, of which the company has the only available technology. Further, the analyst believes this is a "big step" toward accelerated adoption of Cerus' INTERCEPT platform. Brokmeier reiterates a Buy rating and $9 price target on the shares.
08/29/16
CANT
08/29/16
NO CHANGE
CANT
Cerus should be bought at current levels, says Cantor
Cantor analyst Bryan Brokmeier recommends that investors buy Cerus' stock after the FDA recommended that all U.S. blodd centers implement either blood testing for the Zika Virus or FDA-approved pathogen-reduction technology. The analyst says that Cerus is the sole provider of the latter technology. He keeps a $9 price target and Buy rating on the shares.
CEMI Chembio Diagnostics

08/02/16
CHLM
08/02/16
NO CHANGE
Target $10
CHLM
Buy
Chembio could double revenue based on Zika opportunity, says Craig-Hallum
Craig-Hallum analyst Bill Bonello believes Chembio Diagnostics shares can double over the next two years as the $1.5B rapid test market shifts from traditional technology to Chembio's proprietary DPP technology, adding that he think's Chembio could double revenue based on the Zika opportunity alone. The DPP technology is on the market today for detection of STD's, but that opportunity is "dwarfed by fever illness," Bonello tells investors. The firm reiterates its Buy rating and $10 price target on Chembio shares.
11/04/15
BNCH
11/04/15
INITIATION
Target $6
BNCH
Speculative Buy
Chembio Diagnostics initiated with a Speculative Buy at Benchmark
Target $6.
11/04/15
11/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Allegiance Bancshares (ABTX) initiated with a Market Perform at Keefe Bruyette... BioDelivery Sciences (BDSI) initiated with a Buy at Cantor... Cabela's (CAB) initiated with an Overweight at Barclays... Cara Therapeutics (CARA) initiated with a Buy at Cantor... Chembio Diagnostics (CEMI) initiated with a Speculative Buy at Benchmark... Depomed (DEPO) initiated with a Buy at Cantor... Dick's Sporting (DKS) initiated with an Equal Weight at Barclays... Egalet (EGLT) initiated with a Buy at Cantor... Flexion (FLXN) initiated with a Buy at Cantor... HP Enterprise (HPE) initiated with a Buy at UBS... HP Inc. (HPQ) initiated with a Neutral at UBS... Opexa Therapeutics (OPXA) initiated with a Buy at Chardan... Smith & Nephew (SNN) initiated with a Neutral at Sterne Agee CRT... Stryker (SYK) initiated with a Neutral at Sterne Agee CRT... The Medicines Co. (MDCO) initiated with a Buy at Chardan... Tonix Pharmaceuticals (TNXP) initiated with a Buy at Cantor... Vail Resorts (MTN) initiated with a Buy at Janney Capital... Wright Medical (WMGI) initiated with a Buy at Sterne Agee CRT... Zimmer Biomet (ZBH) initiated with a Buy at Sterne Agee CRT.
NLNK NewLink Genetics
$14.95

-0.65 (-4.17%)

05/10/16
CANT
05/10/16
NO CHANGE
Target $20
CANT
Buy
NewLink Genetics price target lowered to $20 from $62 at Cantor
Cantor Fitzgerald analyst Mara Goldstein noted that NewLink Genetics' IMPRESS trial failed to meet its OS endpoint and said the results suggest little chance of a salvageable outcome, but thinks that the company's IDO platform can be "an important valuation backstop" for the shares and is well discounted after the post-failure pullback. Goldstein cut her price target on NewLink to $20 from $62, but maintains a Buy rating on the stock, citing the potential for the IDO platform as well as the company's Ebola vaccine.
03/22/16
BARD
03/22/16
INITIATION
Target $27
BARD
Outperform
NewLink Genetics initiated with an Outperform at Baird
Target $27.
03/22/16
BARD
03/22/16
INITIATION
Target $27
BARD
Outperform
NewLink Genetics initiated with an Outperform at Baird
Target $27.
05/10/16
RHCO
05/10/16
DOWNGRADE
RHCO
Neutral
NewLink Genetics downgraded to Neutral from Buy at SunTrust

TODAY'S FREE FLY STORIES

LBTYA

Liberty Global

$36.99

0.56 (1.54%)

06:11
02/27/17
02/27
06:11
02/27/17
06:11
Conference/Events
Liberty Global management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

AES

AES Corp.

$11.93

0.18 (1.53%)

06:10
02/27/17
02/27
06:10
02/27/17
06:10
Earnings
AES Corp. sees 8%-10% annual growth in EPS, cash flow through 2020 »

Expects 8% to 10% average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

AES

AES Corp.

$11.93

0.18 (1.53%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Earnings
AES Corp. reports Q4 adjusted EPS 35c, consensus 36c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

SHOO

Steven Madden

$37.15

-0.1 (-0.27%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Upgrade
Steven Madden rating change  »

Steven Madden upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SYT

Syngenta

$85.27

0.3 (0.35%)

06:09
02/27/17
02/27
06:09
02/27/17
06:09
Periodicals
ChemChina's Syngenta bid seen receiving conditional EU approval, Reuters says »

The EU is set to give…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCRX

BioCryst

$5.49

-0.11 (-1.96%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Hot Stocks
BioCryst reports 'positive' interim results from APeX-1 trial »

BioCryst Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

JCP

J.C. Penney

$6.46

-0.4 (-5.83%)

06:08
02/27/17
02/27
06:08
02/27/17
06:08
Downgrade
J.C. Penney rating change  »

J.C. Penney downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

06:07
02/27/17
02/27
06:07
02/27/17
06:07
Hot Stocks
Buffett says market 'not in bubble territory' or 'anything of the sort' »

Warren Buffett, while…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

, KR

Kroger

$33.29

0.3 (0.91%)

06:06
02/27/17
02/27
06:06
02/27/17
06:06
Periodicals
Wal-Mart launching price-comparison test in U.S., targeting Aldi, Reuters says »

Wal-Mart (WMT) is…

WMT

Wal-Mart

$72.39

1.08 (1.51%)

KR

Kroger

$33.29

0.3 (0.91%)

PG

Procter & Gamble

$91.05

-0.08 (-0.09%)

UN

Unilever; also tag UL

$46.91

0.33 (0.71%)

UL

Unilever; also tag UN

$47.12

0.22 (0.47%)

CAG

Conagra Brands

$41.16

0.66 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 14

    Mar

  • 19

    Mar

LJPC

La Jolla

$19.87

1.65 (9.06%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Hot Stocks
La Jolla announces positive results from ATHOS-3 Phase 3 study of LJPC-501 »

La Jolla Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

INVH

Invitation Homes

$21.60

0.02 (0.09%)

06:05
02/27/17
02/27
06:05
02/27/17
06:05
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEG

PSEG

$45.61

1.36 (3.07%)

06:04
02/27/17
02/27
06:04
02/27/17
06:04
Downgrade
PSEG rating change  »

PSEG downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Hot Stocks
Breaking Hot Stocks news story on UCP, Inc. »

UCP, Inc. reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LAUR

Laureate Education

$13.24

0.06 (0.46%)

06:03
02/27/17
02/27
06:03
02/27/17
06:03
Initiation
Laureate Education initiated  »

Laureate Education…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$11.35

-0.05 (-0.44%)

06:02
02/27/17
02/27
06:02
02/27/17
06:02
Earnings
UCP, Inc. reports Q4 EPS 89c with benefits, consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

SNAP

Snap Inc.

06:01
02/27/17
02/27
06:01
02/27/17
06:01
Periodicals
Snap founders tightened grip following dispute with Lightspeed, NYT reports »

Early Snap investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

GRAM

Grana y Montero

$3.32

-1.77 (-34.77%)

06:00
02/27/17
02/27
06:00
02/27/17
06:00
Downgrade
Grana y Montero rating change  »

Grana y Montero…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$21.60

0.02 (0.09%)

05:59
02/27/17
02/27
05:59
02/27/17
05:59
Initiation
Invitation Homes initiated  »

Invitation Homes…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.66

0.13 (0.10%)

, EBAY

eBay

$34.06

0.46 (1.37%)

05:58
02/27/17
02/27
05:58
02/27/17
05:58
Periodicals
Tech firms plan to file brief in favor of transgender rights, Axios reports »

Leading tech companies…

AAPL

Apple

$136.66

0.13 (0.10%)

EBAY

eBay

$34.06

0.46 (1.37%)

IBM

IBM

$181.35

-0.3 (-0.17%)

MSFT

Microsoft

PYPL

PayPal

$43.07

0.54 (1.27%)

CRM

Salesforce

$81.78

-0.29 (-0.35%)

YELP

Yelp

$33.46

-0.01 (-0.03%)

BOX

Box

$17.93

0.41 (2.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 13

    Mar

  • 14

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 22

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 09

    May

AFL

Aflac

$71.71

-0.01 (-0.01%)

05:57
02/27/17
02/27
05:57
02/27/17
05:57
Upgrade
Aflac rating change  »

Aflac upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

FTI

TechnipFMC

$32.30

-0.58 (-1.76%)

05:56
02/27/17
02/27
05:56
02/27/17
05:56
Upgrade
TechnipFMC rating change  »

TechnipFMC upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDS

Dillard's

$57.00

2.32 (4.24%)

, ISIL

Intersil

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Dillard's to replace Intersil in S&P 400 as of 2/28 open »

Renesas Electronics Corp.…

DDS

Dillard's

$57.00

2.32 (4.24%)

ISIL

Intersil

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$131.21

9.26 (7.59%)

, SE

Spectra Energy

$40.68

-0.32 (-0.78%)

05:55
02/27/17
02/27
05:55
02/27/17
05:55
Hot Stocks
Incyte to replace Spectra Energy in S&P 500 as of 2/28 open »

Spectra Energy (SE) is…

INCY

Incyte

$131.21

9.26 (7.59%)

SE

Spectra Energy

$40.68

-0.32 (-0.78%)

ENB

Enbridge

$41.34

-0.37 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

  • 06

    Mar

  • 14

    Mar

  • 01

    Apr

  • 19

    Apr

NCMI

National CineMedia

$12.08

-0.35 (-2.82%)

05:53
02/27/17
02/27
05:53
02/27/17
05:53
Recommendations
National CineMedia analyst commentary  »

National CineMedia added…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

HMSY

HMS Holdings

$18.83

0.13 (0.70%)

05:48
02/27/17
02/27
05:48
02/27/17
05:48
Downgrade
HMS Holdings rating change  »

HMS Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.